Research Paper|Volume 13, Issue 2|pp 1729—1741

Anserine, HClO-scavenger, protected against cognitive decline in individuals with mild cognitive impairment

Nobutaka Masuoka¹, Chenxu Lei¹, Haowei Li¹, Noriko Inamura^2,³, Shigenobu Shiotani⁴, Nobuya Yanai⁴, Kenichiro Sato⁴, Keisuke Sakurai¹, Tatsuhiro Hisatsune¹

¹Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
²Community Hearth Promotion Laboratory, Mitsui Fudosan, Co., Ltd., Kashiwa, Japan
³Urban Design Center Kashiwanoha (UDCK), Kashiwa, Japan
⁴Research Division, Tokai Bussan Co., Ltd., Tokyo, Japan

* Present address: Hojo Clinic, Shinagawa, Tokyo, Japan

Received: May 6, 2020Accepted: December 18, 2020Published: January 20, 2021

https://doi.org/10.18632/aging.202535

Copyright: © 2021 Masuoka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Neuroinflammation has been recognized as a promising target when considering strategies for treating AD. In particular, it has been shown that neutrophils and MPO-mediated neuroinflammatory responses with the production of HClO play a role in the progression of AD. In this study, we aimed to evaluate the effects of anserine, a scavenger of HClO, on the protection of cognitive declines in persons with MCI. Fifty-eight elderly volunteers were screened, and 36 MCI individuals were assigned either to an active arm, who received 500 mg anserine per day, or a placebo arm, for 12-weeks. To assess cognitive function, we performed MMSE at baseline and after the ingestion. The data of the MMSE for 30 subjects who completed the follow-up tests were analyzed. A significant difference was detected in the change score of MMSE between the active arm (1.9 ± 2.0; n = 15) and the placebo arm (0 ± 2.8; n = 15) (p = 0.036). After the correction with the daily intake of anserine, the significance was elevated (p = 0.0176). Our results suggest that anserine protects elderly persons with MCI from cognitive declines by suppressing MPO-mediated neuroinflammatory responses.